21 research outputs found
Recommended from our members
Best practices for managing and disseminating resources and outreach and evaluating the impact of the IDG Consortium
The Illuminating the Druggable Genome (IDG) consortium generated reagents, biological model systems, data, informatic databases, and computational tools. The Resource Dissemination and Outreach Center (RDOC) played a central administrative role, organized internal meetings, fostered collaboration, and coordinated consortium-wide efforts. The RDOC developed and deployed a Resource Management System (RMS) to enable efficient workflows for collecting, accessing, validating, registering, and publishing resource metadata. IDG policies for repositories and standardized representations of resources were established, adopting the FAIR (findable, accessible, interoperable, reusable) principles. The RDOC also developed metrics of IDG impact. Outreach initiatives included digital content, the Protein Illumination Timeline (representing milestones in generating data and reagents), the Target Watch publication series, the e-IDG Symposium series, and leveraging social media platforms. Teaser The RDOC was responsible for administering the IDG consortium and disseminating its resources. Best practices for resource management, outreach, and evaluating impacts are reported
A machine learning platform to estimate anti-SARS-CoV-2 activities
Strategies for drug discovery and repositioning are an urgent need with respect to COVID-19. Here we present
"REDIAL-2020", a suite of computational models for estimating small molecule activities in a range of SARS-CoV-2
related assays. Models were trained using publicly available, high throughput screening data and by employing different
descriptor types and various machine learning strategies. Here we describe the development and the usage of eleven
models spanning across the areas of viral entry, viral replication, live virus infectivity, in vitro infectivity and human cell
toxicity. REDIAL-2020 is available as a web application through the DrugCentral web portal
(http://drugcentral.org/Redial). In addition, the web-app provides similarity search results that display the most similar
molecules to the query, as well as associated experimental data. REDIAL-2020 can serve as a rapid online tool for
identifying active molecules for COVID-19 treatment.
</p
DrugCentral 2021 supports drug discovery and repositioning
© 2021 The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research. DrugCentral is a public resource (http://drugcentral.org) that serves the scientific community by providing up-to-date drug information, as described in previous papers. The current release includes 109 newly approved (October 2018 through March 2020) active pharmaceutical ingredients in the US, Europe, Japan and other countries; and two molecular entities (e.g. mefuparib) of interest for COVID19. New additions include a set of pharmacokinetic properties for ∼1000 drugs, and a sex-based separation of side effects, processed from FAERS (FDA Adverse Event Reporting System); as well as a drug repositioning prioritization scheme based on the market availability and intellectual property rights forFDA approved drugs. In the context of the COVID19 pandemic, we also incorporated REDIAL-2020, a machine learning platform that estimates anti-SARS-CoV-2 activities, as well as the \u27drugs in news\u27 feature offers a brief enumeration of the most interesting drugs at the present moment. The full database dump and data files are available for download from the DrugCentral web portal
Recommended from our members
DrugCentral 2018: an update
DrugCentral is a drug information resource (http://drugcentral.org) open to the public since 2016 and previously described in the 2017 Nucleic Acids Research Database issue. Since the 2016 release, 103 new approved drugs were updated. The following new data sources have been included: Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), FDA Orange Book information, L1000 gene perturbation profile distance/similarity matrices and estimated protonation constants. New and existing entries have been updated with the latest information from scientific literature, drug labels and external databases. The web interface has been updated to display and query new data. The full database dump and data files are available for download from the DrugCentral website
Formalizing drug indications on the road to therapeutic intent.
Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent